Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Adenocarcinoma 2Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 10Oxaliplatin 8Capecitabine 8pembrolizumab 6Specimen Handling 6Nivolumab 6Leucovorin 6trastuzumab deruxtecan 5Magnetic Resonance Spectroscopy 5Paclitaxel 4Cisplatin 4Biopsy 4fludarabine 3aldesleukin 3Trastuzumab 3Cyclophosphamide 3zolbetuximab 2fludarabine phosphate 2Ramucirumab 2Folfox protocol 2Docetaxel 2zimberelimab 1zanidatamab 1ulixertinib 1tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × zolbetuximab × 30 days × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-05-04

Spotlight

Astellas Pharma Inc

Phase 3 Active not recruiting
565 enrolled 63 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡